What is the ROCE (Return on Capital Employed) of HLS Therapeutics this year?
The ROCE of HLS Therapeutics is -0.12 undefined this year.
In 2024, HLS Therapeutics's return on capital employed (ROCE) was -0.12, a 12.29% increase from the -0.11 ROCE in the previous year.
HLS Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Analyzing HLS Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
HLS Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Changes in HLS Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
The ROCE of HLS Therapeutics is -0.12 undefined this year.
The ROCE of HLS Therapeutics has increased by 12.29% increased compared to the previous year.
A high Return on Capital Employed (ROCE) indicates that HLS Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.
A low ROCE (Return on Capital Employed) can indicate that HLS Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.
An increase in the ROCE of HLS Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.
A decrease in ROCE of HLS Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.
Some factors that can affect HLS Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.
The ROCE of HLS Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.
To improve the ROCE, HLS Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.
Over the past 12 months, HLS Therapeutics paid a dividend of 0.2 USD . This corresponds to a dividend yield of about 7.9 %. For the coming 12 months, HLS Therapeutics is expected to pay a dividend of 0.18 USD.
The current dividend yield of HLS Therapeutics is 7.9 %.
HLS Therapeutics pays a quarterly dividend. This is distributed in the months of August, November, February, May.
HLS Therapeutics paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0.18 USD are expected. This corresponds to a dividend yield of 7.28 %.
HLS Therapeutics is assigned to the 'Health' sector.
To receive the latest dividend of HLS Therapeutics from 6/15/2023 amounting to 0.05 USD, you needed to have the stock in your portfolio before the ex-date on 4/27/2023.
The last dividend was paid out on 6/15/2023.
In the year 2023, HLS Therapeutics distributed 0.2 USD as dividends.
The dividends of HLS Therapeutics are distributed in USD.
Our stock analysis for HLS Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of HLS Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.